A practical reference on Sirtuin substrate: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Beyond redox chemistry, NAD+ acts as a substrate for several enzyme families. ADP-ribosyltransferases, sirtuins, and CD38 ectoenzymes cleave the molecule into nicotinamide and ADP-ribose or related products. These reactions connect NAD+ availability to processes such as DNA repair, chromatin modification, and calcium signaling. Because the coenzyme is used in both electron transfer and signaling, cells maintain separate pools in compartments including the cytosol, mitochondria, and nucleus. The relative sizes and regulation of those pools remain active areas of study.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is a coenzyme present in all living cells. The molecule consists of two nucleotides linked by phosphate groups, with adenine and a nicotinamide ring as its principal features. In its oxidized form, the nicotinamide ring can accept a hydride ion, becoming NADH. This reversible conversion places NAD+ at the center of many electron-transfer reactions. Its role as a redox carrier is well established across bacteria, plants, fungi, and animals.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide composed of two nucleotides joined by phosphate groups. One nucleotide contains adenine; the other contains nicotinamide. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, and the reversible hydride transfer between them underlies many metabolic oxidation-reduction reactions. In cells, NAD+ serves as an electron acceptor in pathways such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Its concentration and redox ratio vary by compartment, tissue, and metabolic state.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C21H27N7O14P2 | Oxidized free acid form; charge depends on pH. |
| Molar mass | 663.43 g/mol | Calculated for the free acid. |
| CAS Registry Number | 53-84-9 | For the anhydrous free acid; salts have different identifiers. |
| Appearance | White to off-white powder | Solid material; hygroscopic. |
| Solubility | Water-soluble | Dissolves in aqueous buffers; solubility varies with pH and salt. |
Measuring NAD+ in biological samples requires rapid processing because the compound can degrade or interconvert after collection. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and mass spectrometry. Each method has different sensitivity, specificity, and susceptibility to interference from related nucleotides. Sample type matters: cultured cells, animal tissues, and human blood present distinct challenges. Reported values can vary widely across laboratories because of differences in extraction, normalization, and analytical platform. Standardization remains an open issue in the field.
NAD+ is relatively unstable in aqueous solution, especially at neutral or alkaline pH and at elevated temperatures. It is typically stored dry, protected from light and moisture, and kept cold or frozen for long-term use. Solutions are often prepared fresh or buffered to mildly acidic pH to slow hydrolysis. Repeated freeze-thaw cycles can reduce integrity. Laboratories may verify concentration using ultraviolet absorbance at 259 nm or by enzymatic assay. These handling practices are general laboratory conventions rather than universal rules.
Research on NAD+ often examines changes with age, diet, exercise, and disease states, but causal relationships are difficult to establish. Some studies measure NAD+ levels, while others assess enzyme activity or downstream markers. In the literature, terms such as "NAD+ decline" and "NAD+ boosting" appear in both scientific and commercial contexts, sometimes without precise definitions. Whether changes in measured NAD+ directly produce health effects remains an open question. Results from cells, animals, and humans cannot be assumed to translate directly.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
Stability studies show that NAD+ can hydrolyze under prolonged heat, extreme pH, or microbial contamination. Phosphate buffers near neutral pH are often used for short-term handling, though exact stability depends on concentration, temperature, and matrix. In biological samples, endogenous enzymes can rapidly degrade NAD+, making cold chain and fast processing important. Analytical reports should state extraction conditions, internal standards, and validation parameters. Without those details, comparisons across studies remain difficult and potentially misleading.
Related compounds include NADH, the reduced form, and NADP+, which carries an additional phosphate group. NADP+ and NADPH often serve in biosynthetic and antioxidant reactions, while NAD+ and NADH are more associated with energy-yielding catabolism. Nicotinamide, nicotinic acid, and nicotinamide riboside are precursors that can enter salvage pathways. The exact contribution of dietary precursors to tissue NAD+ pools is an area of active investigation. Some studies measure labeled precursors to trace those routes.
NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a coenzyme built from two nucleotides joined by a phosphate linkage. One nucleotide carries adenine, and the other carries nicotinamide; the plus sign denotes a formal positive charge on the nicotinamide ring, not a free proton. In cells, NAD+ and its reduced partner NADH form a reversible redox pair. That pair participates in electron transfer reactions throughout metabolism. The abbreviation NAD+ is common in biochemistry, while NAD(H) sometimes denotes the combined pool.
The molecule was first described in the early twentieth century as a factor that promoted fermentation in yeast extracts. Later work linked it to hydrogen transfer and to the oxidation of nutrients in living tissues. Its structure was resolved as a dinucleotide, which explained why it could accept and donate electrons at specific enzyme sites. Today, NAD+ is recognized as a central substrate and signaling precursor, not merely a metabolic cofactor. Whether all observed NAD+ changes reflect causal signaling remains an open question.
Alprazolam has typically caused anterograde amnesia effects (inability to recall new events), but a study conducted on mice by the Department of Pharmaceutical Sciences and Drug Research at Punjabi University has also determined that alprazolam can produce retrograde amnesic effects (inability to remember events occurring before amnesia). One 2016 study found that "chronic administration of alprazolam affects memory but attentive and psychomotor performance remained unaffected". A 2016 randomized controlled trial stated that "overall, long-term benzodiazepine users may not be in their full cognitive state upon withdrawal". Similarly, a 2017 meta-analysis concluded that "a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal".
== History == Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016. The US Food and Drug Administration (FDA) approved nemolizumab for the treatment of prurigo nodularis based on evidence from two clinical trials (OLYMPIA 1 and OLYMPIA 2) of 560 participants with prurigo nodularis. The trials were conducted at 132 sites in 16 countries including Austria, Belgium, Canada, Denmark, France, Netherlands, Germany, Hungary, Italy, Poland, South Korea, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The trials included 99 participants inside the United States. Among the 560 enrolled participants, all of them were evaluated for efficacy (intent-to-treat population) and 556 participants were evaluated for safety. In both trials, participants with prurigo nodularis were randomized to receive nemolizumab or placebo. Participants weighing less than 90 kilograms (200 lb) in the nemolizumab group received subcutaneous injections of nemolizumab 60 mg at week 0, followed by 30 mg injections every four weeks. Participants weighing 90 kilograms (200 lb) or more in the nemolizumab group received subcutaneous injections of nemolizumab 60 mg at week 0 and every four weeks.
== In popular culture == In 2016, Singaporean director Boo Junfeng directed and released a film titled Apprentice, starring Firdaus Rahman and Wan Hanafi Su. The film, which narrates the fictional story of newly appointed prison officer and executioner Aiman Yusof, touched on the subject of the death penalty in Singapore and an executioner's perspective of the practice, as well as the experiences and ostracisation of the families when their loved ones were tried and executed. The director also revealed that he had gathered information through interviews of the retired executioners, imams and priests who counselled the death row inmates, and also the families of the executed prisoners while producing the film. The film, which was released in several international film festivals, was met with positive public responses and it attracted both nominations and awards for the director and production team. In Singapore, there were local crime shows like In Cold Blood, Crimewatch, and True Files which re-enact the real-life crimes in Singapore. Among these cases, there were murder and drug trafficking cases which attract the death penalty in the city-state. Often, the re-enactments of these capital cases would also show the final verdicts of the convicts, where it revealed the dates of their sentencing and/or executions. Notably, executed criminals like English serial killer John Martin Scripps, child killer Adrian Lim, notorious wife-killer Anthony Ler and cop-killer Zainal Abidin Abdul Malik featured in these re-enactment shows since the 1980s till the present.
Sources: en.wikipedia.org
Candidates were asked to give yes or no responses to whether or not January 6 was an "inside job" and whether or not the 2020 election was "stolen". Those that did not say yes to both answers were not hired.
==== Merger ==== Glaxo and Wellcome merged in 1995, to form Glaxo Wellcome plc. The merger was then considered the biggest in the UK corporate history. Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in Stevenage, Hertfordshire. Also that year, Glaxo Wellcome acquired the California-based Affymax, a leader in the field of combinatorial chemistry. By 1999, Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent. Its products included Imigran (for the treatment of migraine), salbutamol (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). In 1999, the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS. It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent, London and Verona (Italy), and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East.
Aerosol mass spectrometry has also found its way into the field of pharmaceutical aerosol analysis, due to its ability to provide real-time measurements of particle size and chemical composition. People who suffer from chronic respiratory disease commonly receive their medication through the use of either pressurized metered dose inhaler (pMDI) or dry powder inhaler (DPI). In both methods the drug is delivered directly into the lungs by inhalation. In recent years, inhaled products have become available which deliver two types of drug within a single dose. Research has shown that the two drugs inhalers provide an enhanced clinical effect beyond that achieved when the two drugs are administered concurrently from two separate inhalers. It was determined using an AToFMS that the respirable particles in a DPI product and pMDI product were composed of co-associated active pharmaceutical ingredients, which is the reason behind the increased effects of the two drug inhalers.
Sources: en.wikipedia.org
NAD+ is a coenzyme found in living cells and is the oxidized form of nicotinamide adenine dinucleotide. It accepts electrons in redox reactions and also serves as a substrate for certain signaling and repair enzymes.
NAD+ becomes NADH when it accepts a hydride ion during oxidation-reduction reactions. NADH then donates electrons to other molecules, after which the carrier can return to the NAD+ form.
No, nicotinamide is a smaller molecule and a component of NAD+. Cells can use nicotinamide to rebuild NAD+ through the salvage pathway.
NAD+ is a coenzyme found in all living cells. It carries electrons in metabolic reactions and also serves as a substrate for enzymes involved in signaling and DNA repair. Its oxidized and reduced forms are central to energy metabolism.